Physician profile
Robert Hunter
NPI 1942586987
$2,492.13
in general payments reported to CMS, 2019-2025
14 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $566 · 2021: $311 · 2022: $170 · 2023: $80.73 · 2024: $244 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $1,205.96 | 2019-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Omni Hysteroscope |
| Ferring Pharmaceuticals INC. | $378.00 | 2019-2025 | Menopur |
| Emd Serono, INC. | $269.75 | 2019-2025 | |
| Coopersurgical, INC. | $247.04 | 2019-2025 | Stripper, Origio Sequential Fert |
| Baxter Healthcare | $92.07 | 2022 | |
| Organon LLC | $66.43 | 2023-2024 | Ganirelix Acetate, Pregnyl, Follistim Aq |
| Abbvie INC. | $50.48 | 2019 | |
| Galen US INC | $46.43 | 2019-2020 | |
| Hamilton Thorne, INC. | $36.04 | 2025 | Continuous Single Culturenx (Cscmnx), Lenshooke Semen Quality Analyzer, Lykos |
| Merck Sharp & Dohme LLC | $34.67 | 2019 | |
| Becton, Dickinson and Company | $17.76 | 2021 | |
| Ascend Therapeutics US, LLC | $17.30 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.35 | 2021 | |
| Therapeuticsmd, INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.